Revised: August 2, 2026
Accepted: October 16, 2026
Published online: November 20, 2026
Processing time: 141 Days and 1.4 Hours
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 1.3 billion people worldwide and is frequently associated with car
Core Tip: Metainflammation contributes to the pathogenesis of numerous metabolic disorders and chronic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-associated liver disease (MetALD). It promotes hepatic lipid accumulation, inflammation, fibrosis, and cell death, thereby accelerating the progression of MASLD or MetALD to cirrhosis and liver cancer. Therapeutic strategies targeting metainflammation, including gut microbiome-directed therapies, dietary modulation, antioxidant interventions, and modulation of lipid me
- Citation: Zhang CY, Yang M. Metabolic inflammation in metabolic dysfunction-associated steatotic liver disease. World J Immunol 2026; 16(3): 125225
- URL: https://www.wjgnet.com/2219-2824/full/v16/i3/125225.htm
- DOI: https://dx.doi.org/10.5411/wji.125225
The liver is the largest internal organ in the human body and plays important roles in detoxification, metabolism, immunity, and numerous other physiological functions[1]. Metabolic inflammation, also known as metainflammation, is a form of chronic and low-grade inflammation induced by metabolic dysfunction that contributes to many metabolic diseases[2]. Metainflammation links obesity to insulin resistance, type 2 diabetes (T2D), and other metabolic disorders[3,4]. Obesity is a major contributor to metabolic dysfunction-associated steatotic liver disease (MASLD) and a driver for its progression to metabolic dysfunction-associated steatohepatitis (MASH) and end-stage liver diseases[5]. Individuals with metabolically healthy obesity remain at a higher risk of developing MASLD and experiencing the progression of liver fibrosis than those with metabolically healthy normal weight or waist circumference[6].
MASLD affects approximately 1.3 billion people worldwide[7], and its incidence is positively associated with the increasing incidence of obesity and type 2 diabetes. In addition to liver-related complications, MASLD increases the risk of cardiovascular diseases, chronic kidney diseases, T2D, and cancers[8]. Both intrahepatic and extrahepatic metainflammation play critical roles in the progression of MASLD to end-stage liver diseases, including liver cirrhosis and hepatocellular carcinoma. Furthermore, metabolic risk factors and alcohol consumption act synergistically to promote chronic liver diseases. Accordingly, metabolic dysfunction and alcohol-related liver disease (MetALD) refers to steatotic liver disease resulting from the combination of metabolic dysfunction and moderate-to-high alcohol consumption, defined as alcohol intake exceeding the threshold of 20 g daily (140 g/week) for women and 30 g daily (210 g/week) for men[9-11]. In contrast, regardless of the metabolic risk factors (e.g., obesity and type-2 diabetes mellitus), alcohol-associated liver disease (ALD) is defined by alcohol consumption exceeding 350 g/week for women and 420 g/week for men[9].
Metainflammation contributes to the pathogenesis of both MASLD and MetALD through multiple mechanisms, including insulin resistance[12,13], lipid metabolism dysregulation[14,15], oxidative stress[16,17], fibrosis[18,19], and alterations of gut microbiota[20,21]. However, the crosstalk between organs during metainflammation and the dynamic and systemic processes remain incompletely understood. This review discusses the underlying mechanisms of metainflammation in MASLD and MetALD and summarizes current and emerging relevant therapeutic options evaluated in animal models and clinical trials.
In both MASLD and MetALD, meta-inflammation is a predominant driver for the progression of steatosis to steatohepatitis, cirrhosis, and liver cancer[22]. Inflammation regulates both intracellular and intercellular communications or interactions between hepatocytes and immune cells and profoundly influences their metabolic functions. In the healthy liver, Kupffer cells (KCs) are the predominant innate immune cells, accounting for about 70% of total immune cells and playing essential roles in liver homeostasis[23]. During the development of MASLD or MetALD, monocyte-derived macrophages (MDMs) are recruited to the liver, where they remodel immune responses within the steatotic microenvironment[24,25]. For example, one study demonstrated that V-set and immunoglobulin domain-containing 4 -expressing liver-resident KCs exert protective effects against MASH by reducing lipid accumulation in hepatocytes and suppressing hepatic stellate cell (HSC) activation, and decreasing the expression of profibrotic markers, such as alpha-smooth muscle actin (α-SMA)[26]. In contrast, dietary lipids, such as cholesterol, can alter the inflammatory responses and phenotypes of both liver-resident KCs and recruited MDMs in steatotic livers, thereby promoting the progression of MASH[27].
The pathogenic mechanisms underlying MASLD and MetALD are complex and multifactorial, including insulin resistance, dysregulation of lipid metabolism, oxidative stress, cell death (e.g., pyroptosis), fibrosis, and alterations in the gut microbiota. Metainflammation contributes to these pathogenic factors in MASLD and MetALD through different molecular signaling pathways[28]. In this section, we discuss how metainflammation regulates these pathogenic factors during the development and progression of MASLD and MetALD.
MASLD is commonly associated with obesity, T2D, and insulin resistance[29]. Adipose tissue maintains lipid metabolic homeostasis and provides energy through lipolysis[30]. Insulin resistance disrupts lipid metabolic homeostasis, enhances lipolysis in adipose tissues, and increases free fatty acid (FFA) production, resulting in hepatic fat accumulation[31]. Therefore, abnormal lipolysis or excessive FFA production triggers the development of MASLD and MetALD.
Adipose tissue dysfunction can increase FFA production and flux into the liver, leading to hepatic lipid accumulation and lipotoxic injury to further promote metabolic dysfunction and inflammation[32,33]. Overexpression of the Klotho-beta gene in HepG2 cells reduced FFA-induced lipid accumulation and inhibited lipopolysaccharide (LPS)-induced inflammation and phosphorylation of nuclear factor kappa-light-chain-enhancer of activated B cells [nuclear factor kappaB (NF-κB, p65)][34]. Mitochondrial dysfunction disrupts fatty acid oxidation and energy production, thereby linking inflammation, lipid accumulation, and oxidative stress[35,36].
Metainflammation and oxidative stress act synergistically to promote metabolic dysfunction, linking obesity to numerous diseases[37-39]. Excessive or low-dose continuous fructose intake promotes MASLD development through multiple mechanisms. For example, consumption of low-dose (10%) fructose for 8-12 weeks increased reactive oxygen species (ROS) production and suppressed antioxidant defense mechanisms, as evidenced by reduced levels of antioxidant glutathione, glutathione peroxidase, and superoxide dismutase. This resulted in hepatic oxidative stress, as indicated by increased malondialdehyde, a biomarker for lipid peroxidation[40]. Excessive ROS production that exceeds the cellular antioxidant capacity can cause oxidative stress. Lipotoxicity in hepatocytes also increases ROS production, resulting in hepatocyte death and liver injury. Knockdown of AKR1B10 (aldo-keto reductase family 1 member B10) or overexpression of CYP2C19 (cytochrome P450 family 2 subfamily C member 19) decreased FFA-induced oxidative stress and inflammation in hepatocytes by reducing ROS production[41].
Tumor necrosis factor-α (TNF-α) plays an important role in the progression of MASLD to MASH. A hyper-nutritive medium promoted the expression of inflammatory cytokines and chemokines [e.g., interleukin (IL)-8 or IL-8 and C-C motif chemokine ligand 2 or CCL2], as well as pro-fibrotic genes in human precision-cut liver slices. Supplementation of TNF-α further accelerated inflammatory responses and fibrogenesis[42]. In MASLD, TNF-α is primarily produced by KCs and infiltrating monocyte-derived macrophages[43,44].
Zhu et al[45] reported that hepatocyte-specific overexpression of cytidine/uridine monophosphate kinase 2 promoted the progression of MASLD to MASH by inducing NOD-like receptor family pyrin domain containing 3 inflammasome activation and hepatic pyroptosis.
Adipokines, including TNF-α, interleukin-6 or IL-6, and leptin secreted from adipose tissues, induce hepatic metainflammation, immune cell activation, and HSC activation, which may lead to end-stage liver diseases[46,47]. Asprosin (ASP) is a fasting-induced glucogenic protein hormone secreted from white adipose tissues. Plasma ASP levels were elevated in mice and humans with insulin resistance[48] and in patients with newly diagnosed T2D[49]. ASP deficiency alleviated high-fat diet (HFD)-induced hepatic steatosis and inflammation in MASLD mice compared with control animals. Mechanistically, in vitro experiments demonstrated that ASP treatment exacerbated FFA-induced hepatocyte injury in LO2 cells. In vivo studies revealed that ASP deficiency was associated with reduced expression of peroxisome proliferator-activated receptor γ (PPARγ), fatty acid synthase, forkhead box protein O1, and ROS production and inhibited activation of IκB kinase/NF-κB p65 signaling pathway[50]. On the contrary, another study reported that serum ASP levels were significantly lower in patients with liver cirrhosis than in non-cirrhotic patients and healthy individuals. In patients with chronic liver diseases, serum ASP levels were negatively associated with liver fibrosis[51]. These contradictory results suggest that ASP may be implicated in liver fibrosis development and progression. However, its causal or beneficial role and the underlying mechanism in liver fibrosis remain to be clarified.
Tonicity-responsive enhancer-binding protein has also been identified as a key stress-responsive transcription factor in hepatocytes that mediates liver inflammation and fibrosis in MASH[52]. Furthermore, hepatocyte-specific Tonebp knockout significantly reduced hepatic expression of fibrosis-related genes encoding collagens and α-SMA in male mice fed either a methionine- and choline-deficient diet or a high-fat, high-carbohydrate diet[52].
Within the gut-liver axis, gut microbiota-derived metabolites modulate hepatic inflammation and fibrosis by modulating immune responses through immune-metabolic crosstalk[53]. These metabolites include short-chain fatty acids (SCFAs), secondary bile acids, trimethylamine N-oxide, tryptophan derivatives, and endogenous ethanol[54,55]. For example, SCFAs are produced by the fermentation of dietary fibers by gut microbiota, primarily including acetate, propionate, and butyrate. They play important roles in the regulation of host immune responses by regulating macrophage polarization and T cell activation through activation of G protein-coupled receptors[56]. In addition, SCFAs also regulate liver fat and glucose metabolism and insulin sensitivity to impact metabolic liver diseases[57,58].
Gut microbiota dysbiosis in MASLD[59] and ALD[60] impairs intestinal barrier integrity and increases circulating endotoxin levels, resulting in hepatic inflammation and injury. Alteration of the gut microbiota during obesity can decrease the expression of intestinal tight junction proteins, thereby disrupting intestinal barrier integrity[61,62], such as a reduction in beneficial bacteria such as Faecalibacterium and enrichment of proinflammatory bacteria such as Enterobacteriaceae. Gut microbiota dysbiosis alters the production of microbial metabolites such as SCFAs and increases circulating endotoxin levels, which can promote hepatic inflammation and fibrosis through the gut–liver axis[63]. Alcohol consumption further increases the abundance of pathogenic intestinal bacteria, alters fecal pH value, and elevates plasma endotoxin levels, thereby exacerbating liver inflammation and injury[64].
Mice with intestinal epithelial-specific hypoxia-inducible factor 1 alpha knockout exhibited more severe hepatic lipid accumulation and injury than wild-type mice, accompanied by increased gut dysbiosis and serum levels of liver injury enzyme alanine aminotransferase (ALT) and endotoxin[65]. Gut inflammation also alters the intestinal luminal milieu, thereby promoting microbial dysbiosis[66,67]. Collectively, these findings suggest that modulation of gut microbiota can influence both the metabolic and immunological functions of the liver, causing metainflammation.
Adipokines are bioactive molecules secreted from adipose tissues, and some of which promote the development of MASLD, MetALD, and liver fibrosis. For example, leptin is essential for liver fibrosis development in chronic liver disease regardless of etiology and is required for the bioactivity of transforming growth factor beta 1[68]. In contrast, adiponectin exerts multiple protective effects against the development of MASLD or MetALD by enhancing glycolysis and fatty acid oxidation[69,70]. In addition, adiponectin plays an essential role in regulating inflammation by suppressing LPS-induced ROS production and ethanol-induced TNF-α production in KCs[71-73].
Overall, metainflammation contributes to the development and progression of MASLD and MetALD, and many molecular signaling pathways and components are involved in this process (Figure 1).
Treatment of vitamin D3 and DOPA-33 (a dioxopiperidinamide derivative) significantly suppressed hepatic lipid accumulation, oxidative stress, and hepatocyte apoptosis in zebrafish models of MASLD by reducing the production of ROS and enhancing antioxidant defense responses[74]. Oral administration of vitamin D3 for 12 weeks in mice with T2D attenuated hepatic steatosis by reducing lipogenesis and enhancing lipid oxidation and hepatic autophagy through activation of the AMP-activated protein kinase (AMPK) signaling pathway and inhibition of protein kinase B/mammalian target of rapamycin signaling pathway[75]. Increased consumption of vitamins C and E was independently associated with a reduced risk of MASLD development in a five-year follow-up study while studying the association between the com
Diet plays a central role in the development of MASLD and MetALD by regulating systemic inflammation and metabolic dysfunction[77]. Dietary interventions, including adherence to the Mediterranean diet[78] and intermittent fasting[79], can alter gut microbiota composition, improve insulin sensitivity, and restore lipid metabolism homeostasis, thereby reducing liver injury. In obese mice, a low-carbohydrate, HFD enriched with ω-3 polyunsaturated fatty acids (PUFAs) promoted greater body weight loss and increased serum inflammatory cytokines, such as IL-17 and IL-33, compared with the control mice[80]. Compared with a saturated-enriched low-carbohydrate diet, diets enriched with ω-9 PUFAs increased the expression of uncoupling protein 1 and peroxisome proliferator-activated receptor gamma coactivator 1-alpha, thereby enhancing mitochondrial function in brown adipose tissues[81]. Furthermore, consumption of a hypocaloric diet for six months significantly reduced body weight and body mass index (BMI) while improving hepatic steatosis, inflammation, and antioxidant function in patients with MASLD[82].
In a study with a median follow-up of 10.49 years, higher dietary fiber intake was inversely associated with the risk of MASLD and with liver fat content measured by magnetic resonance imaging[83]. A clinical trial demonstrated that dietary fiber supplementation (24 g/day, soluble fiber:Insoluble fiber = 5:19) in a cereal meal for 12 weeks significantly reduced hemoglobin A1c (HbA1c), fasting plasma glucose, and fibrosis-4 index scores in patients with T2D and MASLD compared with the control group[84]. Another clinical trial showed that prebiotic fiber supplementation combined with weight loss counseling resulted in a greater reduction in trunk fat than placebo. This effect was associated with increased Bifidobacterium abundance and the preservation of taurine and hypotaurine metabolism[85]. However, the source and amount of dietary fiber may influence its effectiveness. One clinical study found that 12 weeks of dietary fiber supplementation (11.7 g/day of oat bran or spelt bran) did not improve hepatic steatosis or alter the overall gut microbial composition or bile acid profile[86]. However, BMI and serum markers of liver injury (alanine aminotransferase or ALT, aspartate aminotransferase or aspartate transaminase (AST), and gamma-glutamyl transferase or γ-GT) were significantly reduced during the 3-week run-in phase[86].
A recent study reported that treatment with KN21, a novel direct AMPK activator, significantly reduced the liver-to-body weight ratio and hepatic steatosis in mice fed a choline-deficient, L-amino acid-defined HFD. Mechanistically, KN21 treatment enhanced AMPK phosphorylation, thereby reducing long-chain triacylglycerol accumulation and restoring homeostasis of pyrimidine metabolism[87].
Treatment of PPARγ agonist pioglitazone protected T2D- and sepsis-induced liver damage in mice by increasing AMPK phosphorylation[88]. Treatment with β-hydroxybutyrate also alleviated hepatic lipid accumulation in db/db mice and palmitic acid-treated AML12 hepatocytes by activating PPARα-regulated lipid oxidation signaling pathway[89].
Emerging microbiome-directed therapies for MASLD and MetALD include the above-discussed new dietary formulation or modulation[90], bariatric surgery[91], and modulation of gut microbiota through prebiotics, probiotics, synbiotics, fecal microbiota transplantation (FMT), and bacteriophage therapy[92]. Supplementation of Bacteroides eggerthii ameliorated Western diet -induced hepatic steatosis, inflammation, and fibrosis in male C57BL/6J mice by increasing levels of me
Furthermore, combining different therapeutic strategies may synergistically improve metabolic dysfunction and reduce inflammation. For instance, the synergistic treatment of synbiotics and antioxidants significantly ameliorated MASLD pathogenic features through modulation of gut microbiota and downregulation of HFD-induced inflammation and oxidative stress[95]. Multifunctional products may also be used to treat MASLD and MetALD. For example, the soluble fiber pectin enhances probiotic viability and antioxidant stability in fermented pear juice[96]. In addition, treatment with tomato pectin ameliorated hepatic steatosis and inflammation in mice fed a HFD[97].
Metainflammation and chronic low-grade systemic inflammation are closely associated with many metabolic disorders, including MASLD and MetALD. Therapeutic strategies targeting lipid metabolism, insulin resistance, and gut microbiota modulation have shown promise in improving metabolic disorders and reducing metainflammation. Sixty patients with MASLD and T2D received weekly subcutaneous injections of HEC88473 (5.1-68.0 mg), a dual agonist of glucagon-like peptide-1 and fibroblast growth factor 21 (FGF21), or placebo for 5 weeks. The greatest relative reduction in magnetic resonance imaging proton density fat fraction (MRI-PDFF) was observed in the 30.6 mg cohort compared with the placebo group (-47.21% vs -15.05%; P = 0.0143), whereas the greatest reduction in HbA1c was observed in the 68.0 mg cohort compared with the placebo group (-1.10% vs -0.31%)[98]. After treatment with pegozafermin (BIO89-100), a glycoPEGylated analog of FGF21, 12 of 19 patients (63%) met the primary endpoint, defined as a ≥ 2-point improvement in the MASLD Activity Score, accompanied by a ≥ 1-point improvement in either hepatocellular ballooning or lobular inflammation, with no worsening of fibrosis. Improvement in fibrosis with no worsening of MASH was observed in 26% of patients, while NASH resolution without worsening of fibrosis occurred in 32%. A significant improvement was also observed in least-squares mean relative change from baseline in MRI-PDFF was -64.7% (95%CI: -71.7% to -57.7%; P < 0.0001), as well as in serum markers for liver injury, fibrosis, and lipids[99]. Its pharmacokinetics, pharmacodynamics, efficacy, and safety in patients with MASH-associated compensated cirrhosis are currently being evaluated in phase II and III clinical trials[100].
A single-center phase II study has demonstrated that lanifibranor, a pan-PPAR agonist, improved glucose and lipid metabolism and reduced hepatic and peripheral insulin resistance, thereby ameliorating hepatic steatosis in patients with MASLD and T2D[101]. Another multicenter, double-blind, phase II clinical trial study showed that treatment with another pan-PPAR agonist, chiglitazar (48 mg or 64 mg), for 18 weeks significantly reduced liver fat content, as assessed MRI-PDFF, in patients with MASLD, hypertriglyceridemia, and insulin resistance[102].
Modulation of gut microbiota has also emerged as a promising therapeutic strategy for MASLD. Probiotics modulate the gut microbiome to ameliorate MASLD. A randomized, double-blind, placebo-controlled trial demonstrated that supplementation with Lactobacillus delbrueckii subsp. Lactis at a dose of 9 × 109 CFU/day decreased serum ALT and AST levels, Lactobacillus helveticus [LH001] reduced body weight, and Pediococcus pentosaceus KID7 [PPKID7] decreased total cholesterol levels (186.1 ± 7.0 mmol/L to 178.0 ± 7.9 mmol/L, P = 0.03)[103]. The primary endpoint of this trial was met in the improvement in liver function with decrease in the abundance of Proteobacteria and an increase in the abundance of Ruminococcaceae and Lachnospiraceae in the LL001 treatment group[103]. In addition, a phase IV clinical trial showed that three consecutive FMTs increased the alpha diversity of gut microbiota in patients with MASLD. Although FMT did not improve hepatic steatosis and liver biochemical parameters, the abundance of two genera, Stercorousia and Alistipes putredinis, was associated with serum triglyceride levels[104].
Several additional therapeutic interventions have also been evaluated in clinical trials. For example, consumption of Fonte Essenziale® mineral water improved intestinal permeability by increasing the expression of occluding and claudin 1 while reducing circulating LPS levels. It also attenuated systemic inflammation by reducing expression of interleukin-1β, TNF-α, and IL-6, and alleviated oxidative stress as assessed by the reactive oxygen metabolites and biological antioxidant potential tests[105]. Dihydromyricetin, the principal bioactive component of the plant Ampelopsis grossedentata, reduced liver injury and insulin resistance while improving glucose and lipid metabolism in patients with MASLD[106]. It also effectively improved glycemic control and renal function in adults with T2D by lowering fasting plasma glucose, retinol-binding protein-4, and others[107].
The above-discussed treatments (Table 1) ameliorate liver injury, metabolic dysfunction, oxidative stress, and gut health to improve metainflammation. Furthermore, adaptation of metabolic drugs, bariatric surgery, nutritional counseling, and lifestyle modification have been listed in clinical practice[108-110]. Importantly, identification of non-invasive biomarkers, patient stratification for precision therapy, and mechanism-based therapeutic strategies should be considered in the treatment of MASLD and MetALD.
| Drugs | Clinical trials | Phases | Mechanisms/aims | Ref. |
| HEC88473, a dual agonist of GLP-1 and FGF21 | NCT05943886 | 1 | Improvement in glycemic control and lipid metabolism. Reduction in hepatic fat fraction | [98] |
| Pegozafermin | NCT04048135; NCT04929483; NCT06419374 | 1/2; 2; 3 | Improvement in glycemic control, serum lipids, and liver injury and fibrosis | [99,100] |
| Lanifibranor, a PPAR pan-agonist | NCT03459079 | 2 | Improvement in glucose and lipid metabolism. Inhibition of hepatic and peripheral insulin resistance | [101] |
| Chiglitazar, a PPAR pan-agonist | NCT05193916 | 2 | Improvement of liver injury. Reduction in liver fat content | [102] |
| Probiotics: LL001, LH001, and PPKID7 | NCT04555434 | 1/2 | Improvement in liver injury. Body weight loss. Reduction in total cholesterol | [103] |
| Three consecutive FMTs | NCT04465032 | 4 | Change of gut microbiota alpha diversity | [104] |
| Fonte essenziale | NCT07211113 | Not applicable | Reduction of intestinal permeability. Inhibition of systemic inflammation and oxidative stress | [105] |
| Dietary supplementation with dihydromyricetin, vitamin C, E, and choline | NCT05052515 | Not applicable | Antioxidant activity and glycemic control. Improvement in sugar and lipid metabolism | [106,107] |
Overall, metainflammation is closely associated with metabolic disorders and tissue inflammation across multiple organs (Figure 2). Obesity-associated metainflammation is associated with metabolic disorders affecting multiple organs[111-114], including the liver, heart, lungs, kidneys, pancreas, and intestine.
Metabolic inflammation (metainflammation) serves as a key mechanistic link between metabolic liver diseases and other metabolic disorders, including obesity and T2D. Therapeutic strategies targeting metainflammation, such as anti-inflammatory and antioxidant agents, interventions that reduce lipid accumulation, and gut microbiome–targeted therapies, can attenuate hepatic inflammation, steatosis, cell death (e.g., pyroptosis), and fibrosis, thereby preventing the progression of MASLD and MetALD to cirrhosis and liver cancer. Because both MASLD and MetALD arise from multiple pathogenic mechanisms, combination therapies represent a promising therapeutic approach.
Metainflammation is a dynamic, systemic process. Developing multi-organ models to investigate the underlying cellular and molecular mechanisms of metainflammation, identifying noninvasive biomarkers, and designing precise therapeutic strategies to restore immune homeostasis and resolve inflammation are becoming increasingly important. The integration of multi-omics approaches and artificial intelligence is expected to guide and accelerate future research in this field.
| 1. | Robinson MW, Harmon C, O'Farrelly C. Liver immunology and its role in inflammation and homeostasis. Cell Mol Immunol. 2016;13:267-276. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 965] [Cited by in RCA: 908] [Article Influence: 90.8] [Reference Citation Analysis (17)] |
| 2. | Charles-Messance H, Mitchelson KAJ, De Marco Castro E, Sheedy FJ, Roche HM. Regulating metabolic inflammation by nutritional modulation. J Allergy Clin Immunol. 2020;146:706-720. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 20] [Cited by in RCA: 84] [Article Influence: 14.0] [Reference Citation Analysis (0)] |
| 3. | Santamarina AB, Calder PC, Estadella D, Pisani LP. Anthocyanins ameliorate obesity-associated metainflammation: Preclinical and clinical evidence. Nutr Res. 2023;114:50-70. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 24] [Reference Citation Analysis (0)] |
| 4. | Zhang Y, Ding H, Zhao X, Li Y, Ge P. The immunometabolic network in obesity-associated insulin resistance: a systemic multi-organ and multi-cellular perspective. Int Immunopharmacol. 2026;177:116528. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 5. | Quek J, Chan KE, Wong ZY, Tan C, Tan B, Lim WH, Tan DJH, Tang ASP, Tay P, Xiao J, Yong JN, Zeng RW, Chew NWS, Nah B, Kulkarni A, Siddiqui MS, Dan YY, Wong VW, Sanyal AJ, Noureddin M, Muthiah M, Ng CH. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8:20-30. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 563] [Cited by in RCA: 583] [Article Influence: 194.3] [Reference Citation Analysis (5)] |
| 6. | Man S, Lv J, Yu C, Deng Y, Yin J, Wang B, Li L, Liu H. Association between metabolically healthy obesity and non-alcoholic fatty liver disease. Hepatol Int. 2022;16:1412-1423. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 3] [Cited by in RCA: 20] [Article Influence: 5.0] [Reference Citation Analysis (0)] |
| 7. | Miller DM, McCauley KF, Dunham-Snary KJ. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances. Endocrinol Diabetes Metab. 2025;8:e70132. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 76] [Reference Citation Analysis (2)] |
| 8. | Sandireddy R, Sakthivel S, Gupta P, Behari J, Tripathi M, Singh BK. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. Front Cell Dev Biol. 2024;12:1433857. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 141] [Cited by in RCA: 172] [Article Influence: 86.0] [Reference Citation Analysis (1)] |
| 9. | Marek GW, Malhi H. MetALD: Does it require a different therapeutic option? Hepatology. 2024;80:1424-1440. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 16] [Cited by in RCA: 33] [Article Influence: 16.5] [Reference Citation Analysis (1)] |
| 10. | Gao B, Arab JP, Liangpunsakul S, Ding WX, Szabo G, Mehal W, Wang H, He Y, Stärkel P, Llorente C, Schnabl B, Hwang S, Vandermerwe S, Gao Y, Zheng MH, Kim W, George J, Bataller R, Loomba R, Leggio L, Tacke F. Metabolic dysfunction and alcohol-associated liver disease (MetALD). eGastroenterology. 2025;3:e100319. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 31] [Cited by in RCA: 29] [Article Influence: 29.0] [Reference Citation Analysis (1)] |
| 11. | Gratacós-Ginès J, Ariño S, Sancho-Bru P, Bataller R, Pose E. MetALD: Clinical aspects, pathophysiology and treatment. JHEP Rep. 2025;7:101250. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 30] [Reference Citation Analysis (0)] |
| 12. | Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821-1830. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 6709] [Cited by in RCA: 2488] [Article Influence: 108.2] [Reference Citation Analysis (6)] |
| 13. | Kardinal R, Wachten D. Macrophages in metaflammation - fueling chronic inflammation in metabolic disease. Pflugers Arch. 2025;478:10. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 11] [Cited by in RCA: 9] [Article Influence: 9.0] [Reference Citation Analysis (0)] |
| 14. | Ertunc ME, Hotamisligil GS. Lipid signaling and lipotoxicity in metaflammation: indications for metabolic disease pathogenesis and treatment. J Lipid Res. 2016;57:2099-2114. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 411] [Cited by in RCA: 381] [Article Influence: 38.1] [Reference Citation Analysis (4)] |
| 15. | Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol Endocrinol Metab. 2008;295:E10-E16. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 165] [Cited by in RCA: 158] [Article Influence: 8.8] [Reference Citation Analysis (2)] |
| 16. | Contreras-Zentella ML, Hernández-Espinosa LC, Hernández-Muñoz R. Oxidative Stress in Liver Metabolic Dysfunction and Diseases, with a Focus on Hepatogenic Diabetes: Effect of Alcohol Consumption. Antioxidants (Basel). 2025;14:1494. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 7] [Reference Citation Analysis (2)] |
| 17. | Ma Y, Lee G, Heo SY, Roh YS. Oxidative Stress Is a Key Modulator in the Development of Nonalcoholic Fatty Liver Disease. Antioxidants (Basel). 2021;11:91. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 174] [Cited by in RCA: 172] [Article Influence: 34.4] [Reference Citation Analysis (2)] |
| 18. | Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A. Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease. World J Gastroenterol. 2020;26:1993-2011. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 78] [Cited by in RCA: 82] [Article Influence: 13.7] [Reference Citation Analysis (8)] |
| 19. | Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: clinical implications beyond alcoholic liver disease. World J Gastroenterol. 2014;20:2168-2175. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 37] [Cited by in RCA: 44] [Article Influence: 3.7] [Reference Citation Analysis (0)] |
| 20. | Abenavoli L, Scarlata GGM, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B, Roncada P, Luzza F. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. Medicina (Kaunas). 2023;59:594. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 31] [Reference Citation Analysis (0)] |
| 21. | Balakrishnan J, Kannan S, Arivazhagan G, Ramachandran N, Sundarasamy VG. Understanding the interconnected roles of gut microbiota and metabolomic profiles in alcoholic liver disease pathophysiology and their potential for innovative treatment strategies. Med Microecol. 2025;26:100154. [DOI] [Full Text] |
| 22. | Kim Y, Park Y, Rho H, Yao T, Gao B, Hwang S. Inflammation in MASLD progression and cancer. JHEP Rep. 2025;7:101414. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 20] [Cited by in RCA: 41] [Article Influence: 41.0] [Reference Citation Analysis (2)] |
| 23. | González Del Barrio L, Ipsen DH, Pfister DR, Hancz D, Scott CL. Targeting macrophages in liver fibrosis. Front Immunol. 2026;17:1835489. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 2] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 24. | Daemen S, Gainullina A, Kalugotla G, He L, Chan MM, Beals JW, Liss KH, Klein S, Feldstein AE, Finck BN, Artyomov MN, Schilling JD. Dynamic Shifts in the Composition of Resident and Recruited Macrophages Influence Tissue Remodeling in NASH. Cell Rep. 2021;34:108626. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 60] [Cited by in RCA: 327] [Article Influence: 65.4] [Reference Citation Analysis (2)] |
| 25. | Remmerie A, Martens L, Thoné T, Castoldi A, Seurinck R, Pavie B, Roels J, Vanneste B, De Prijck S, Vanhockerhout M, Binte Abdul Latib M, Devisscher L, Hoorens A, Bonnardel J, Vandamme N, Kremer A, Borghgraef P, Van Vlierberghe H, Lippens S, Pearce E, Saeys Y, Scott CL. Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver. Immunity. 2020;53:641-657.e14. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 118] [Cited by in RCA: 516] [Article Influence: 86.0] [Reference Citation Analysis (2)] |
| 26. | Li HY, Fu SW, Wu JC, Li ZH, Xu MY. Vsig4(+) resident single-Kupffer cells improve hepatic inflammation and fibrosis in NASH. Inflamm Res. 2023;72:669-682. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 7] [Reference Citation Analysis (0)] |
| 27. | McGettigan B, McMahan R, Orlicky D, Burchill M, Danhorn T, Francis P, Cheng LL, Golden-Mason L, Jakubzick CV, Rosen HR. Dietary Lipids Differentially Shape Nonalcoholic Steatohepatitis Progression and the Transcriptome of Kupffer Cells and Infiltrating Macrophages. Hepatology. 2019;70:67-83. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 97] [Cited by in RCA: 101] [Article Influence: 14.4] [Reference Citation Analysis (0)] |
| 28. | Guo Y, Ma Q, Guo Z, Chu J, Wu N, Qi Y. Inflammation-mediated diabetes-liver disease cross-organ crosstalk: From molecular mechanisms to precision therapeutic strategies. Life Sci. 2026;402:124534. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (2)] |
| 29. | Dong L, Lin S, Slavin J, Gunnam S, Cheng Z, Nie S, Leeming MG, Williamson NA, Montgomery MK. Phosphatidylserine Supplementation Improves Metabolic Liver Disease and Glycemic Control in the Presence of Suppressed Oxidative Glucose Metabolism. Diabetes. 2026;75:273-287. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 3] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 30. | Zhao J, Wu Y, Rong X, Zheng C, Guo J. Anti-Lipolysis Induced by Insulin in Diverse Pathophysiologic Conditions of Adipose Tissue. Diabetes Metab Syndr Obes. 2020;13:1575-1585. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 19] [Cited by in RCA: 66] [Article Influence: 11.0] [Reference Citation Analysis (0)] |
| 31. | Goto H, Takamura T. Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated by Diabetes: Pathophysiology and Emerging Therapies. J Obes Metab Syndr. 2025;34:224-238. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 20] [Reference Citation Analysis (0)] |
| 32. | Romanos M, Garcia Cordova JM, Villamarin J, Pazmino Zurita JD, Acosta A. Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Literature Review on Pathophysiology and Treatment. Diabetes Obes Metab. 2026;28 Suppl 2:19-30. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 11] [Cited by in RCA: 18] [Article Influence: 18.0] [Reference Citation Analysis (0)] |
| 33. | Zhao Q, Lu S, Guan Y, Sun Z, Qiu S, Zhang A. Dysregulation of the AMPK-SREBP1-FASN axis in MASLD: driving a vicious cycle of lipotoxicity and metabolic-immune crosstalk. Lipids Health Dis. 2026;25:62. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 9] [Reference Citation Analysis (0)] |
| 34. | Meroni M, Panera N, Paolini E, Longo M, Tiano F, De Stefanis C, D'Oria V, Mosca A, Badiali S, Maggioni M, Mosca E, Fracanzani AL, Alisi A, Dongiovanni P. The KLB rs12152703 variant confers protection against hepatic inflammation in patients with MASLD by boosting Klotho-beta expression. JHEP Rep. 2026;8:101717. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 35. | Sunny NE, Bril F, Cusi K. Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies. Trends Endocrinol Metab. 2017;28:250-260. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 278] [Cited by in RCA: 268] [Article Influence: 29.8] [Reference Citation Analysis (0)] |
| 36. | Zhang CY, Yang M. Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment. Explor Med. 2021;2:494-510. [RCA] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 37. | Pinheiro D, Cornachione AS. Cellular and molecular pathways linking obesity to skeletal muscle dysfunction. Mol Biol Rep. 2026;53:978. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 38. | Kountouras J, Polyzos SA, Vardaka E, Zavos C, Doulberis M. Chronic infection and metabolic stress: a converging axis driving hypertension and MASLD outcomes. Am J Hypertens. 2026;hpag064. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 39. | Calcaterra V, Cena H, Conti MV, Scavone IAM, Basilico S, Quatrale A, Zuccotti G. Dietary polyphenols in pediatric obesity and cardiometabolic risk: mechanisms and clinical evidence. Front Nutr. 2026;13:1849842. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 40. | Arifin M, Jannah W, Zakiyah N, Meiliana A, Barliana MI, Lestari K. Fructose Diet-Induced Liver Injury Through Oxidative Stress: A Systematic Review of Preclinical Studies. J Nutr Metab. 2026;2026:1644860. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 41. | Liu K, Zhang B, Tang Y, Tan Z, Bu Y, Lv Y. Integrative Multi-Omics Analysis Elucidates the Progressive Disease Landscape and Reveals Dynamic Protein Biomarkers for MASLD Surveillance. FASEB J. 2026;40:e71998. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 42. | Luo K, Li M, Gorter AR, Oosterhuis D, de Meijer VE, Olinga P. Effects of TNF-α in Human Precision-Cut Liver Slices and its Implications for Metabolic Dysfunction-Associated Steatohepatitis Progression. Inflammation. 2026;49:183. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 43. | Cha JY, Kim DH, Chun KH. The role of hepatic macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Lab Anim Res. 2018;34:133-139. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 35] [Cited by in RCA: 66] [Article Influence: 8.3] [Reference Citation Analysis (0)] |
| 44. | Vahrenbrink M, Coleman CD, Kuipers S, Lurje I, Hammerich L, Kunkel D, Keye J, Dittrich S, Schjeide BM, Hiß R, Müller J, Püschel GP, Henkel J. Dynamic changes in macrophage populations and resulting alterations in Prostaglandin E(2) sensitivity in mice with diet-induced MASH. Cell Commun Signal. 2025;23:227. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 9] [Reference Citation Analysis (1)] |
| 45. | Zhu S, Liao L, Zhong Y, Liu Z, Lu J, Yang Z, Xiao Y, Xu X. Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025;83:383-396. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 21] [Reference Citation Analysis (2)] |
| 46. | Gastaldelli A, Scoditti E, Macedo MP. Metabolic drivers of MASLD and MASH: from hormonal imbalance to fibrosis. Diabetologia. 2026;69:3088-3104. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 6] [Cited by in RCA: 8] [Article Influence: 8.0] [Reference Citation Analysis (0)] |
| 47. | Lopes KG, Souza MDGC, Lopes FAM, da Silva Junior VL, Terra CA, Carvalho ATP, Bouskela E, Kraemer-Aguiar LG. Associations Between Inflammatory Adipokines, Liver Steatosis, and Fibrosis in Patients with Different Degrees of Adiposity with or Without Metabolic Syndrome. Horm Metab Res. 2025;57:529-534. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (2)] |
| 48. | Romere C, Duerrschmid C, Bournat J, Constable P, Jain M, Xia F, Saha PK, Del Solar M, Zhu B, York B, Sarkar P, Rendon DA, Gaber MW, LeMaire SA, Coselli JS, Milewicz DM, Sutton VR, Butte NF, Moore DD, Chopra AR. Asprosin, a Fasting-Induced Glucogenic Protein Hormone. Cell. 2016;165:566-579. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 208] [Cited by in RCA: 408] [Article Influence: 40.8] [Reference Citation Analysis (0)] |
| 49. | Diao H, Fan X, Li Z, Hou L, Dong Z, Pang S. Circulating asprosin concentrations in individuals with new-onset type 2 diabetes and prediabetes. Diabetes Res Clin Pract. 2024;213:111730. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (0)] |
| 50. | Wang C, Zeng W, Wang L, Xiong X, Chen S, Huang Q, Zeng G, Huang Q. Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species. Drug Dev Res. 2024;85:e22213. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 13] [Cited by in RCA: 8] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 51. | Wang S, Wang Y, Zhang S, Li T, Zhou X, Chen L. Serum asprosin level is significantly lower in patients with liver cirrhosis than in those with non-cirrhotic chronic liver diseases. Front Endocrinol (Lausanne). 2025;16:1691224. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (2)] |
| 52. | Lee JH, Song H, Yoo EJ, Jeong Y, Ko SM, Shin GW, Choi GE, Jee Y, Kang M, Yang J, Hur SP, Park JE, Lee Y, Park HK, Yun JH, Jang MK, Lee-Kwon W, Kwon HM, Choi SY. Hepatocyte TonEBP promotes metabolic stress-induced hepatic fibroinflammation involving transcriptional activation of ELR⁺ CXC chemokines. Cell Death Discov. 2026;12:116. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 2] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 53. | Sahu P, Satapathy T. The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets. Probiotics Antimicrob Proteins. 2026. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 54. | Che Z, Xue W, Zhao X, Hu C, Tian Y. Regulatory Role and Biomarker Potential of Gut Microbiota Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease to Hepatocellular Carcinoma. Clin Transl Gastroenterol. 2025;16:e00914. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 7] [Cited by in RCA: 9] [Article Influence: 9.0] [Reference Citation Analysis (1)] |
| 55. | Lau HC, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2025;22:619-638. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 65] [Reference Citation Analysis (0)] |
| 56. | Ghosh D, Yadav A, Pandey D. Immunomodulatory roles of gut-derived short-chain fatty acids in periodontal inflammation and homeostasis. Explor Immunol. 2026;6:1003238. [RCA] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 57. | Zhang CY, Liu S, Sui YX, Yang M. Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. World J Hepatol. 2025;17:113756. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 5] [Reference Citation Analysis (0)] |
| 58. | Weitkunat K, Stuhlmann C, Postel A, Rumberger S, Fankhänel M, Woting A, Petzke KJ, Gohlke S, Schulz TJ, Blaut M, Klaus S, Schumann S. Short-chain fatty acids and inulin, but not guar gum, prevent diet-induced obesity and insulin resistance through differential mechanisms in mice. Sci Rep. 2017;7:6109. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 117] [Cited by in RCA: 162] [Article Influence: 18.0] [Reference Citation Analysis (2)] |
| 59. | Zhou Z, Pan X, Ni J, Lou Z, Shen Y, Jiang S, Dong X, Wang F, Chen Y, Li L. Akkermansia muciniphila ameliorates acute liver injury aggravated by MASLD-associated dysbiosis via daidzein/PPAR-α/NF-κB signaling. Food Funct. 2026;17:4717-4728. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (10)] |
| 60. | Zhou Z, Zhong W. Targeting the gut barrier for the treatment of alcoholic liver disease. Liver Res. 2017;1:197-207. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 64] [Cited by in RCA: 87] [Article Influence: 9.7] [Reference Citation Analysis (1)] |
| 61. | Yang-Jensen SK, Nägele NS, Jensen BAH. From gut to blood: barrier dysfunction as a driver of systemic low-grade inflammation in cardiometabolic disease. Am J Physiol Cell Physiol. 2025;329:C1723-C1741. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 16] [Cited by in RCA: 19] [Article Influence: 19.0] [Reference Citation Analysis (13)] |
| 62. | Di Vincenzo F, Del Gaudio A, Petito V, Lopetuso LR, Scaldaferri F. Gut microbiota, intestinal permeability, and systemic inflammation: a narrative review. Intern Emerg Med. 2024;19:275-293. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1010] [Cited by in RCA: 977] [Article Influence: 488.5] [Reference Citation Analysis (12)] |
| 63. | Rusman RD, Akil F, Parewangi ML, Daud NA, Bachtiar R, Kusuma SH, Rifai A. Gut microbiota and metabolic-associated steatosis liver disease: Unveiling mechanisms and opportunities for therapeutic intervention. World J Exp Med. 2025;15:107316. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in CrossRef: 8] [Cited by in RCA: 8] [Article Influence: 8.0] [Reference Citation Analysis (3)] |
| 64. | Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, Gobejishvili L, Joshi-Barve S, Ayvaz T, Petrosino J, Kong M, Barker D, McClain C, Barve S. Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One. 2013;8:e53028. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 465] [Cited by in RCA: 443] [Article Influence: 34.1] [Reference Citation Analysis (10)] |
| 65. | Shao T, Zhao C, Li F, Gu Z, Liu L, Zhang L, Wang Y, He L, Liu Y, Liu Q, Chen Y, Donde H, Wang R, Jala VR, Barve S, Chen SY, Zhang X, Chen Y, McClain CJ, Feng W. Intestinal HIF-1α deletion exacerbates alcoholic liver disease by inducing intestinal dysbiosis and barrier dysfunction. J Hepatol. 2018;69:886-895. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 110] [Cited by in RCA: 207] [Article Influence: 25.9] [Reference Citation Analysis (8)] |
| 66. | Stecher B. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection. Microbiol Spectr. 2015;3. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 99] [Cited by in RCA: 169] [Article Influence: 16.9] [Reference Citation Analysis (0)] |
| 67. | Winter SE, Lopez CA, Bäumler AJ. The dynamics of gut-associated microbial communities during inflammation. EMBO Rep. 2013;14:319-327. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 225] [Cited by in RCA: 274] [Article Influence: 21.1] [Reference Citation Analysis (0)] |
| 68. | Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol. 2002;37:206-213. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 327] [Cited by in RCA: 301] [Article Influence: 12.5] [Reference Citation Analysis (6)] |
| 69. | Khoramipour K, Chamari K, Hekmatikar AA, Ziyaiyan A, Taherkhani S, Elguindy NM, Bragazzi NL. Adiponectin: Structure, Physiological Functions, Role in Diseases, and Effects of Nutrition. Nutrients. 2021;13:1180. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 30] [Cited by in RCA: 234] [Article Influence: 46.8] [Reference Citation Analysis (0)] |
| 70. | Combs TP, Marliss EB. Adiponectin signaling in the liver. Rev Endocr Metab Disord. 2014;15:137-147. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 128] [Cited by in RCA: 120] [Article Influence: 10.0] [Reference Citation Analysis (5)] |
| 71. | Park PH, Thakur V, Pritchard MT, McMullen MR, Nagy LE. Regulation of Kupffer cell activity during chronic ethanol exposure: role of adiponectin. J Gastroenterol Hepatol. 2006;21 Suppl 3:S30-S33. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 32] [Cited by in RCA: 36] [Article Influence: 1.8] [Reference Citation Analysis (2)] |
| 72. | Thakur V, Pritchard MT, McMullen MR, Nagy LE. Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 2006;290:G998-1007. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 104] [Cited by in RCA: 116] [Article Influence: 5.8] [Reference Citation Analysis (0)] |
| 73. | Kishore R, Hill JR, McMullen MR, Frenkel J, Nagy LE. ERK1/2 and Egr-1 contribute to increased TNF-alpha production in rat Kupffer cells after chronic ethanol feeding. Am J Physiol Gastrointest Liver Physiol. 2002;282:G6-15. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 89] [Cited by in RCA: 97] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 74. | Dharshan SS, Ramamurthy K, Kaliraj S, Manikandan K, Chitra V, Rajagopal R, Alfarhan A, Namasivayam SKR, Kathiravan MK, Arockiaraj J. Combined effects of vitamin D3 and dioxopiperidinamide derivative on lipid homeostasis, inflammatory pathways, and redox imbalance in non-alcoholic fatty liver disease in vivo zebrafish model. Biotechnol Appl Biochem. 2025;72:320-339. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 4] [Cited by in RCA: 26] [Article Influence: 26.0] [Reference Citation Analysis (0)] |
| 75. | Lim H, Lee H, Lim Y. Effect of vitamin D(3) supplementation on hepatic lipid dysregulation associated with autophagy regulatory AMPK/Akt-mTOR signaling in type 2 diabetic mice. Exp Biol Med (Maywood). 2021;246:1139-1147. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 11] [Cited by in RCA: 28] [Article Influence: 5.6] [Reference Citation Analysis (0)] |
| 76. | Sepehrinia M, Bazmi S, Nikparast A, Etesami E, Vahid F, Javdan G, Rozbahani H, Razaz JM, Kuchay MS, Homayounfar R. Composite dietary antioxidant index and risk of metabolic dysfunction - associated steatotic liver disease: evidence from a prospective cohort study. Nutr Metab (Lond). 2026;23:86. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 77. | Wu W, Hou Z. Association of the dietary index for gut microbiota and dietary inflammation index with metabolic dysfunction-associated steatotic liver disease and metabolic alcohol-associated liver disease. Front Immunol. 2025;16:1593245. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 5] [Reference Citation Analysis (3)] |
| 78. | Wang Z, Chen G, Sun X, Xiao J, Kong L, Jiang S, Xu T, Wang M, Zhao H. Multi-omics integration reveals the impact of mediterranean diet on hepatic metabolism and gut microbiota in mice with metabolic dysfunction-associated steatotic liver disease. Front Nutr. 2025;12:1644014. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 3] [Cited by in RCA: 6] [Article Influence: 6.0] [Reference Citation Analysis (0)] |
| 79. | Lin X, Zhu X, Xin Y, Zhang P, Xiao Y, He T, Guo H. Intermittent Fasting Alleviates Non-Alcoholic Steatohepatitis by Regulating Bile Acid Metabolism and Promoting Fecal Bile Acid Excretion in High-Fat and High-Cholesterol Diet Fed Mice. Mol Nutr Food Res. 2023;67:e2200595. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1] [Cited by in RCA: 12] [Article Influence: 4.0] [Reference Citation Analysis (4)] |
| 80. | Santamarina AB, Moreira RG, Mennitti LV, Martins Ferreira YA, Jucá A, Prado CM, Pisani LP. Low-carbohydrate diet enriched with omega-3 and omega-9 fatty acids modulates inflammation and lipid metabolism in the liver and white adipose tissue of a mouse model of obesity. Nutr Metab Cardiovasc Dis. 2025;35:103932. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 81. | Ferreira YAM, Santamarina AB, Mennitti LV, de Souza EA, Prado CM, Pisani LP. Unsaturated fatty acids enhance mitochondrial function and PGC1-α expression in brown adipose tissue of obese mice on a low-carbohydrate diet. J Nutr Biochem. 2025;140:109873. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 2] [Cited by in RCA: 3] [Article Influence: 3.0] [Reference Citation Analysis (0)] |
| 82. | Elhoseeny MM, Rageh F, Bakry N, Elgamal R, Ahmed SS, Rezk SM, Othman AAA. Culturally adapted hypocaloric diet improves hepatic steatosis, inflammatory and oxidative biomarkers in Egyptian MASLD patients: a single-arm interventional study. Lipids Health Dis. 2025;24:286. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 7] [Reference Citation Analysis (4)] |
| 83. | Jiang J, Liu Y, Yang H, Ma Z, Liu W, Zhao M, Peng X, Qin X, Xia Y. Dietary fiber intake, genetic predisposition of gut microbiota, and the risk of metabolic dysfunction-associated steatotic liver disease. Food Res Int. 2025;211:116497. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 4] [Reference Citation Analysis (1)] |
| 84. | Chen XS, Liu HZ, Huang F, Meng J, Fang JX, Han Y, Zou HM, Gu Q, Hu X, Ma QW, Han YX, Wang SJ. Impact of a high dietary fiber cereal meal intervention on the progression of liver fibrosis in T2DM with MASLD. Front Endocrinol (Lausanne). 2025;16:1623136. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 85. | Mayengbam S, Raman M, Parnell JA, Eksteen B, Lambert JE, Eller LK, Nicolucci AC, Aktary ML, Reimer RA. Effects of combined prebiotic fiber supplementation and weight loss counseling in adults with metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial. Eur J Nutr. 2025;64:144. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 7] [Reference Citation Analysis (1)] |
| 86. | Brandt A, Yergaliyev T, Halibasic E, Cyba A, Jaeger JW, Gong R, Hernández-Arriaga A, Schneider CV, Sjöland W, Molinaro A, Trauner M, Trautwein C, Camarinha-Silva A, Bergheim I, Schneider KM. Fiber enrichment is not superior to dietary monitoring in MASLD: A dual-center, double-blind, placebo-controlled trial. iScience. 2025;28:114019. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 87. | Lee J, Kim S, Ju Y, Seo M, Kim H, Shin JH, Na Y, Kwon Y, Hwang GS. KN21, a direct AMPK activator, alleviates hepatic steatosis and fibrosis by modulating long-chain TAG and pyrimidine metabolism in a MASH mouse model. Biomed Pharmacother. 2025;193:118798. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 3] [Reference Citation Analysis (0)] |
| 88. | Ma J, Qi X, Li W, Feng X, Ma J, Ma H, Man J, Ma T, De T, Liu J, Li H, Li J, Liu M, Li S, Gao J, Wang H, Ma G. Targeted activation of PPARG or AKT1 alleviates liver injury in mice with type 2 diabetes and sepsis by modulating inflammatory and metabolic pathways. Ann Med. 2026;58:2684073. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (1)] |
| 89. | Li D, Zhang L, Li Y, Wu J, Mou Y, He Y, Zhou T, Gong Q, Ma L, Xu Y, Huang W, Gao C. β-Hydroxybutyrate upregulates hepatic histone β-hydroxybutyrylation modification, promotes the expression of PPARα, and alleviates the hepatic steatosis in MASLD. Clin Epigenetics. 2026;18:77. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1] [Cited by in RCA: 2] [Article Influence: 2.0] [Reference Citation Analysis (0)] |
| 90. | Paredes-Marin A, He Y, Zhang X. Dietary Interventions in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review of Evidence, Mechanisms, and Translational Challenges. Nutrients. 2025;17:3491. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 5] [Reference Citation Analysis (4)] |
| 91. | Liu H, Lefere S, Guillot A, Zheng MH, Tacke F. Bariatric surgery for metabolic dysfunction-associated steatotic liver disease (MASLD): Current knowledge of mechanisms. Hepatology. 2025. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 18] [Reference Citation Analysis (0)] |
| 92. | Holmer M, Hagström H, Tillander V, Alkadri M, Petersson S, Brismar TB, Stål P, Lindqvist C. One-year follow-up of short-term dietary intervention for MASLD: sustained improvements in steatosis, weight and dietary intake. Scand J Gastroenterol. 2025;60:1087-1095. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 93. | Choi J, Yoon MG, Jang SH, Baek GO, Jung HS, Lee NR, Lee CH, Han JE, Cheong JY, Eun JW, Kim SS. Bacteroides eggerthii ameliorates metabolic dysfunction-associated steatotic liver disease through host-microbe signaling and highlights 2-hydroxyisocaproate as a potential effector. Clin Mol Hepatol. 2026;32:239-257. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 2] [Cited by in RCA: 4] [Article Influence: 4.0] [Reference Citation Analysis (0)] |
| 94. | Zhou M, Deng Y, Huang Y, Yu C, Chen X, Yang Q, Liao Y, Wang S, Zhang P, Chen A, Ling W, Chen X, Li J, Xue H. Dietary index for gut microbiota, plasma metabolome, and risks of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases. Nutr Metab (Lond). 2026;23:106. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 95. | Xu Z, Zhu W, Xia Q, Huang W, Chi Y, Qi H, Chan OYP, Ching JY, Chan FK, Chan NN, Ng SC. Synbiotics and antioxidants synergistically attenuate disease progression in metabolic dysfunction-associated steatotic liver disease. Biomed Pharmacother. 2026;201:119656. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 96. | Niu D, Zhao D, Yalikun A, Li F. Pectin Supplementation Improves Probiotic Survival and Preserves Bioactive Compounds of Fermented Pear Juice. Foods. 2026;15:2200. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 1] [Reference Citation Analysis (0)] |
| 97. | Wang P, Sun J, Zhao W, Wang D, Ma Y, Zhao Y, Wang Y, Zhao X. Tomato Pectin Ameliorated Hepatic Steatosis in High-Fat-Diet Mice by Modulating Gut Microbiota and Bile Acid Metabolism. J Agric Food Chem. 2024. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 18] [Reference Citation Analysis (0)] |
| 98. | Xiang L, Wang G, Zhuang Y, Luo L, Yan J, Zhang H, Li X, Xie C, He Q, Peng Y, Chen H, Li Q, Li X, Guo L, Lv G, Ding Y. Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82:967-978. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 29] [Cited by in RCA: 36] [Article Influence: 36.0] [Reference Citation Analysis (1)] |
| 99. | Alkhouri N, Lazas D, Loomba R, Frias JP, Feng S, Tseng L, Balic K, Agollah GD, Kwan T, Iyer JS, Morrow L, Mansbach H, Margalit M, Harrison SA. Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023;58:1005-1015. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 5] [Cited by in RCA: 17] [Article Influence: 5.7] [Reference Citation Analysis (0)] |
| 100. | Tseng CL, Balic K, Charlton RW, Margalit M, Mansbach H, Savic RM. Population Pharmacokinetics and Pharmacodynamics of Pegozafermin in Patients with Nonalcoholic Steatohepatitis. Clin Pharmacol Ther. 2023;114:1323-1331. [RCA] [PubMed] [DOI] [Full Text] [Cited by in RCA: 5] [Reference Citation Analysis (4)] |
| 101. | Barb D, Kalavalapalli S, Godinez Leiva E, Bril F, Huot-Marchand P, Dzen L, Rosenberg JT, Junien JL, Broqua P, Rocha AO, Lomonaco R, Abitbol JL, Cooreman MP, Cusi K. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. J Hepatol. 2025;82:979-991. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 60] [Cited by in RCA: 72] [Article Influence: 72.0] [Reference Citation Analysis (0)] |
| 102. | Sun Y, Wu C, Xin G, Zhong B, Wu X, Liu Y, Shi J, Zhang Q, Zhao Y, Gao Y, Xin Y, Zhu Y, Wu L, Mao X, Du J, Shang J, Sun W, Xu J, Yu Z, Nan Y, Sheng H, Li Y, Rao H, Yu C, Cao H, Chen B, Li Z, Wu X, Tong X, You H. Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study. Hepatology. 2026;83:1248-1260. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 9] [Cited by in RCA: 14] [Article Influence: 14.0] [Reference Citation Analysis (3)] |
| 103. | Won SM, Joung H, Park IG, Han SH, Ham YL, Han JS, Kwon Y, Kim DJ, Suk KT. The effects of next generation probiotics on metabolic dysfunction-associated steatotic liver disease: a parallel, double-blind, randomized, placebo-controlled trial. J Transl Med. 2025;24:61. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 7] [Reference Citation Analysis (2)] |
| 104. | Groenewegen B, Ruissen MM, Crossette E, Menon R, Prince AL, Norman JM, Ballieux BEPB, Lamb HJ, Terveer EM, Keller JJ, Tushuizen ME. Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial. Gut Microbes. 2025;17:2541035. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 17] [Cited by in RCA: 24] [Article Influence: 24.0] [Reference Citation Analysis (0)] |
| 105. | Dallio M, Romeo M, Di Nardo F, Senese G, Silvestrin A, Coppola A, Napolitano C, Vaia P, Basile C, Martinelli G, Gregorio A, Federico A. Beneficial Effects of Long-Lasting Bicarbonate-Sulfate-Calcium-Magnesium Water Intake on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Outcomes via Impacting Intestinal Permeability (IP), IP-Related Systemic Inflammation, and Oxidative Stress. Nutrients. 2025;17:3452. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in RCA: 2] [Reference Citation Analysis (0)] |
| 106. | Chen S, Zhao X, Wan J, Ran L, Qin Y, Wang X, Gao Y, Shu F, Zhang Y, Liu P, Zhang Q, Zhu J, Mi M. Dihydromyricetin improves glucose and lipid metabolism and exerts anti-inflammatory effects in nonalcoholic fatty liver disease: A randomized controlled trial. Pharmacol Res. 2015;99:74-81. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 200] [Cited by in RCA: 186] [Article Influence: 16.9] [Reference Citation Analysis (0)] |
| 107. | Ran L, Wang X, Lang H, Xu J, Wang J, Liu H, Mi M, Qin Y. Ampelopsis grossedentata supplementation effectively ameliorates the glycemic control in patients with type 2 diabetes mellitus. Eur J Clin Nutr. 2019;73:776-782. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 16] [Cited by in RCA: 34] [Article Influence: 4.3] [Reference Citation Analysis (0)] |
| 108. | European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 1461] [Cited by in RCA: 1702] [Article Influence: 851.0] [Reference Citation Analysis (14)] |
| 109. | Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology. 2024;79:1212-1219. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 339] [Cited by in RCA: 306] [Article Influence: 153.0] [Reference Citation Analysis (1)] |
| 110. | Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, Kleiner DE, Loomba R. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-1835. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1980] [Cited by in RCA: 2138] [Article Influence: 712.7] [Reference Citation Analysis (12)] |
| 111. | Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity. 2022;55:31-55. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 1670] [Cited by in RCA: 1539] [Article Influence: 384.8] [Reference Citation Analysis (4)] |
| 112. | Yu S, Zhu X, Zhao X, Li Y, Niu X, Chen Y, Ying J. Improvement of chronic metabolic inflammation and regulation of gut homeostasis: Tea as a potential therapy. Pharmacol Ther. 2025;269:108828. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 13] [Cited by in RCA: 13] [Article Influence: 13.0] [Reference Citation Analysis (0)] |
| 113. | Yang M, Liu S, Zhang C. The Related Metabolic Diseases and Treatments of Obesity. Healthcare (Basel). 2022;10:1616. [RCA] [PubMed] [DOI] [Full Text] [Full Text (PDF)] [Cited by in Crossref: 132] [Cited by in RCA: 111] [Article Influence: 27.8] [Reference Citation Analysis (2)] |
| 114. | Tilg H, Ianiro G, Gasbarrini A, Adolph TE. Adipokines: masterminds of metabolic inflammation. Nat Rev Immunol. 2025;25:250-265. [RCA] [PubMed] [DOI] [Full Text] [Cited by in Crossref: 18] [Cited by in RCA: 132] [Article Influence: 132.0] [Reference Citation Analysis (0)] |